www.accesswire.com Open in urlscan Pro
2606:4700:20::ac43:4322  Public Scan

URL: https://www.accesswire.com/917238/stockholders-can-assist-the-schall-law-firm-in-a-securities-fraud-lawsuit-against-cvs-hea...
Submission: On September 18 via manual from US — Scanned from DE

Form analysis 0 forms found in the DOM

Text Content

Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader
Guide, Feedback, and Issue Reporting
 * ABOUT
   * WHO WE ARE
   * WHO WE SERVE
   * CONTACT
 * PRODUCTS
   * PRESS RELEASE DISTRIBUTION
   * PRESS RELEASE OPTIMIZER
   * MEDIA SUITE
   * MEDIA DATABASE
   * MEDIA PITCHING
   * MEDIA MONITORING
   * MEDIA ROOM
   * IR WEBSITES
   * WEBCASTING
 * NEWSROOM
 * RESOURCES
   * LIBRARY
   * BLOG
   * COMPANY SPOTLIGHT
   * PRESS RELEASE SAMPLE
   * PRESS RELEASE TEMPLATE
   * FAQ
 * CUSTOMER REVIEWS
 * LOGIN

SUBMIT A PRESS RELEASE


--------------------------------------------------------------------------------

Back to Newsroom


STOCKHOLDERS CAN ASSIST THE SCHALL LAW FIRM IN A SECURITIES FRAUD LAWSUIT
AGAINST CVS HEALTH CORPORATION

Friday, 13 September 2024 11:00 AM

The Schall Law Firm

Visit Newsroom
Share this Article


Topic:
Class Action

LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a
national shareholder rights litigation firm, reminds investors of a class action
lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for
violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule
10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.



Investors who purchased the Company's securities between May 3, 2023 and April
30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm
before September 10, 2024.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049
Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to
discuss your rights free of charge. You can also reach us through the firm's
website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification
occurs, you are not represented by an attorney. If you choose to take no action,
you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to
the market. CVS failed to properly forecast medical cost trends and health care
utilization rates. The Company was forced to incur material costs due to its
ineffective forecasts. The Company overstated the profitability of its Health
Care Benefits division. Despite its assurances, the Company's profits from other
business segments were not sufficient to cover the increasing expenses incurred
by the Health Care Benefits segment. Based on these facts, the Company's public
statements were false and materially misleading throughout the class period.
When the market learned the truth about CVS, investors suffered damages.

The Schall Law Firm represents investors around the world and specializes in
securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions
under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

Topic:
Class Action
Back to Newsroom


CONTACT US TODAY





IF YOU HAVE QUESTIONS OR WANT TO LEARN MORE ABOUT OUR PRODUCTS, OUR TEAM’S HERE
TO HELP!

Contact Us

--------------------------------------------------------------------------------

ABOUT

WHO WE ARE

WHO WE SERVE

CONTACT

PRODUCTS

PRESS RELEASE DISTRIBUTION

PRESS RELEASE OPTIMIZER

MEDIA SUITE

MEDIA DATABASE

MEDIA PITCHING

MEDIA MONITORING

MEDIA ROOM

IR WEBSITES

WEBCASTING

NEWSROOM

RESOURCES

LIBRARY

FAQ

COMPANY SPOTLIGHT

PRESS RELEASE SAMPLE

PRESS RELEASE TEMPLATE

BLOG

CUSTOMER REVIEWS

LOGIN

CONNECT TODAY!

SALES

EDITORIAL

CONTENT LICENSING

JOIN OUR NEWSLETTER

866-694-3099

--------------------------------------------------------------------------------

© 2024 

ACCESSWIRE | All Rights Reserved 

 * PRIVACY POLICY
 * TERMS OF SERVICE
 * RESPONSIBLE DISCLOSURE GUIDELINES
 * Status






Share by: